Euglycemic (Type of DKA that can be an adverse event with use of SGLT2s) <7.3 (pH criteria for DKA diagnosis) Cerebral Edema (complication of rapidly decreasing BGL in HHS patients (primarily in the young) 126 (Fasting BGL for DM diagnosis) Fluids (most important initial treatment in hyperglycemic emergencies) 6.5 (A1C DM diagnostic criteria) Lactic acidosis (possible complication of hallmark DM oral therapy) 600 (BGL level with HHS glucose diagnostic criteria/max MHS glucommander reading) BHG (replaced AG as diagnostic criteria in latest DKA/HHS guidelines) Kussmals (types of respirations associated with DKA) 50 (average mg/dL drop in BGL per 1 unit rapid acting insulin) 0.5 (units/kg/day; recommend starting dose for new start insulin) Awiqli (newest FDA approved insulin) 1 (units/mL; standard concentration of IV insulin infusion) 300 (BGL cut off to start adding dextrose to fluids in HHS) Basal (another term for long acting insulin) SQUID (protocol/trial that supported the addition of SQ insulin in the magangement of mild DKA) 20 (# mEq of K that should be added to each liter with concurrent insulin infusion) IV (should only be used for patients with DKA/HHS/Hyperkalemia) 0.1 (units/kg/hr for non glucommander DKA/HHS) 320 (Total serum omolarity cut off for HHS) Octerotide (medication that be used in SU/insulin overdose) 3.3 (mimimum mEq/L K should be prior to initiated insulin infusion) 250 (BGL cut off to start adding dextrose to fluids in DKA) LR (fluid choiced for faster resolution of acidosis in DKA) Infection (driver of DKA outside of non compliance and new diagnosis) <6.9 (pH cut off for routine administration of sodium bicarb) Polydipsia, polyphagia, polyuria (hallmark symptoms of uncontrolled/undiagnosed DM) Euglycemic (Type of DKA that can be an adverse event with use of SGLT2s) <7.3 (pH criteria for DKA diagnosis) Cerebral Edema (complication of rapidly decreasing BGL in HHS patients (primarily in the young) 126 (Fasting BGL for DM diagnosis) Fluids (most important initial treatment in hyperglycemic emergencies) 6.5 (A1C DM diagnostic criteria) Lactic acidosis (possible complication of hallmark DM oral therapy) 600 (BGL level with HHS glucose diagnostic criteria/max MHS glucommander reading) BHG (replaced AG as diagnostic criteria in latest DKA/HHS guidelines) Kussmals (types of respirations associated with DKA) 50 (average mg/dL drop in BGL per 1 unit rapid acting insulin) 0.5 (units/kg/day; recommend starting dose for new start insulin) Awiqli (newest FDA approved insulin) 1 (units/mL; standard concentration of IV insulin infusion) 300 (BGL cut off to start adding dextrose to fluids in HHS) Basal (another term for long acting insulin) SQUID (protocol/trial that supported the addition of SQ insulin in the magangement of mild DKA) 20 (# mEq of K that should be added to each liter with concurrent insulin infusion) IV (should only be used for patients with DKA/HHS/Hyperkalemia) 0.1 (units/kg/hr for non glucommander DKA/HHS) 320 (Total serum omolarity cut off for HHS) Octerotide (medication that be used in SU/insulin overdose) 3.3 (mimimum mEq/L K should be prior to initiated insulin infusion) 250 (BGL cut off to start adding dextrose to fluids in DKA) LR (fluid choiced for faster resolution of acidosis in DKA) Infection (driver of DKA outside of non compliance and new diagnosis) <6.9 (pH cut off for routine administration of sodium bicarb) Polydipsia, polyphagia, polyuria (hallmark symptoms of uncontrolled/undiagnosed DM)
(Print)
Euglycemic (Type of DKA that can be an adverse event with use of SGLT2s)
<7.3 (pH criteria for DKA diagnosis)
Cerebral Edema (complication of rapidly decreasing BGL in HHS patients (primarily in the young)
126 (Fasting BGL for DM diagnosis)
Fluids (most important initial treatment in hyperglycemic emergencies)
6.5 (A1C DM diagnostic criteria)
Lactic acidosis (possible complication of hallmark DM oral therapy)
600 (BGL level with HHS glucose diagnostic criteria/max MHS glucommander reading)
BHG (replaced AG as diagnostic criteria in latest DKA/HHS guidelines)
Kussmals (types of respirations associated with DKA)
50 (average mg/dL drop in BGL per 1 unit rapid acting insulin)
0.5 (units/kg/day; recommend starting dose for new start insulin)
Awiqli (newest FDA approved insulin)
1 (units/mL; standard concentration of IV insulin infusion)
300 (BGL cut off to start adding dextrose to fluids in HHS)
Basal (another term for long acting insulin)
SQUID (protocol/trial that supported the addition of SQ insulin in the magangement of mild DKA)
20 (# mEq of K that should be added to each liter with concurrent insulin infusion)
IV (should only be used for patients with DKA/HHS/Hyperkalemia)
0.1 (units/kg/hr for non glucommander DKA/HHS)
320 (Total serum omolarity cut off for HHS)
Octerotide (medication that be used in SU/insulin overdose)
3.3 (mimimum mEq/L K should be prior to initiated insulin infusion)
250 (BGL cut off to start adding dextrose to fluids in DKA)
LR (fluid choiced for faster resolution of acidosis in DKA)
Infection (driver of DKA outside of non compliance and new diagnosis)
<6.9 (pH cut off for routine administration of sodium bicarb)
Polydipsia, polyphagia, polyuria (hallmark symptoms of uncontrolled/undiagnosed DM)
